Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome

Menopause

Volumn 15, Issue 5, 2008, Pages 945-949

  Tejada, Maria Isabel ^a   García Alegría, Eva ^a   Bilbao, Amaia ^b   Martínez Bouzas, Cristina ^a   Beristain, Elena ^a   Poch, Marisa ^c   Ramos Arroyo, Maria A ^d   López, Blanca ^e   Fernandez Carvajal, Isabel ^e   Ribate, Maria Pilar ^f   Ramos, Feliciano ^f  

^a HOSPITAL DE CRUCES   (Spain)

^b Barakaldo   (Spain)

^c HOSPITAL SAN PEDRO   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e UNIVERSITY OF VALLADOLID   (Spain)

^f UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; CGGBP1 PROTEIN, HUMAN; DNA BINDING PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FRAGILE MENTAL RETARDATION1 GENE; FRAGILE X SYNDROME; GENE; HUMAN; MOLECULAR GENETICS; PREMATURE OVARIAN FAILURE; RISK; TRINUCLEOTIDE REPEAT; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SPAIN; X CHROMOSOME INACTIVATION;

ADULT; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OVARIAN FAILURE, PREMATURE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; SPAIN; TRINUCLEOTIDE REPEAT EXPANSION; X CHROMOSOME INACTIVATION;

EID: 58249086882     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181647762     Document Type: Article

References (20)

1. Fu YH, Kuhl DP, Pizzuti A, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 2001;67:1047-1058.
2. Rousseau F, Heitz D, Biancalana V, et al. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N Engl J Med 1991;325:1673-1681.
3. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000;97:189-194.
4. Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. Fertil Steril 2007;87:456-465.
5. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57:127-130.
6. Hagerman PJ, Greco CM, Hagerman RJ. A cerebellar tremor/ataxia syndrome among fragile X premutation carriers. Cytogenet Genome Res 2003;100:206-212.
7. Sullivan AK, Marcus M, Epstein MP, et al. Association of FMRP1 repeat size with ovarian dysfunction. Hum Reprod 2005;20:402-412.
8. Murray A, Ennis S, MacSwiney F, Webb J, Morton NE. Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet 2000;8:247-252.
9. Hundscheid RD, Sistermans EA, Thomas CM, et al. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations. Am J Hum Genet 2000;66:413-428.
10. Mallolas J, Duran M, Sanchez A, et al. Implications of the FMR1 gene in menopause: study of 147 Spanish women. Menopause 2001;8:106-110.
11. Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. Eur J Hum Genet 2006;14:253-255.
12. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000;66:6-15.
13. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72:869-878.
14. García-Alegría E, Ibáñez B, Mínguez M, et al. Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models. RNA 2007;13:756-762.
15. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005;83:1327-1332.
16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1998;16:1215.
17. Duran Domínguez M, Molina Carrillo M, Fernandez Toral J, et al. Diagnóstico molecular por reacción en cadena de la polimerasa del Síndrome X frágil: aplicación de un protocolo diagnóstico en 50 familias del norte de España. Ann Esp Pediatr 2001;54:331-339.
18. Tejada I, Mornet E, Biancalana V, et al. Direct DNA analysis of fragile X syndrome in Spanish pedigrees. Am J Med Genet 1992;43:282-290.
19. Taylor AK, Safanda JF, Fall MZ, et al. Molecular predictors carriers of fragile X syndrome. JAMA 1994;271:552-553.
20. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X Study - preliminary data. Am J Med Genet 1999;83:322-325.